NanoViricides, Inc. Has Filed its Annual Report
NanoViricides(US:NNVC) Accessnewswireยท2025-09-30 12:45Group 1 - The company, NanoViricides, Inc., has reported that its broad-spectrum antiviral NV-387 is currently at the Phase II clinical trial stage, indicating significant progress in its development for respiratory viral infections [1] - The company filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2025, with the SEC on September 29, 2025, which is accessible on the SEC website [1]